BC
ELVN icon

Bridgefront Capital’s Enliven Therapeutics ELVN Stock Holding History

Bridgefront Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Buy
+5,805
New +$161K 0.06% 455

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgefront Capital's ELVN Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 5,805 shares worth $228K. The stake represents 0.06% of the portfolio and ranks #455 among its holdings.

170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Bridgefront Capital held 5,805 shares of Enliven Therapeutics worth $228K as of Q1 2026.
  • Enliven Therapeutics was a new Bridgefront Capital position in Q1 2026.
  • Enliven Therapeutics made up 0.06% of Bridgefront Capital's portfolio in Q1 2026, its #455 holding.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.